Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting



Status:Active, not recruiting
Conditions:Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 40
Updated:10/28/2017
Start Date:March 13, 2017
End Date:December 1, 2017

Use our guide to learn which trials are right for you!

Clomiphene (Clomid) is a drug FDA approved to treat female infertility, however, it is often
used by men in an off-label setting to both treat male infertility and in a multitude of
sports disciplines to increase performance.

Study Objectives:

- Determine detection windows for clomiphene and its metabolites in urine following a
medium-term administration

- Understand the effect of clomiphene administration on luteinizing hormone (LH),
follicle-stimulating hormone (FSH), and serum testosterone (T) concentrations in a
longitudinal manner

- Identify changes in current steroidal module of Athlete Biological Passport

Clomiphene, pharmaceutically prepared as clomiphene citrate, is a selective estrogen receptor
modulator (SERM) with a therapeutic indication to treat female infertility. Though
FDA-approved only for use in women, clomiphene is often prescribed off-label to males to
treat male infertility and secondary hypogonadism due to its ability to increase serum
testosterone levels. Numerous clinical studies have documented both the effectiveness for
these indications and safety of clomiphene administration in males. Increasing the
concentration of circulating testosterone can have additional effects, including the
enhancement of performance in sports. As such, clomiphene is already abused by athletes in
several sporting disciplines, including mixed martial arts, cycling, and bodybuilding.
Therefore, clomiphene is a prohibited substance under the World Anti-Doping Agency code .
Though the parent compound and metabolites of clomiphene are directly detectable in routine
anti-doping screening, the urinary detection window and the effect of clomiphene
administration on other anti-doping markers are unknown and thus the foci of this study.

Inclusion Criteria:

- Active males who engage in regular exercise between the ages of 18 and 40 on the day of
enrollment

• For this study, regular exercise is defined as: physical activity resulting in an
increased heart rate for at least 30 minutes per day, 4-5 days per week.

Exclusion Criteria:

- Individuals outside of the described age range on the day of enrollment

- Individuals who are in a Registered Testing Pool for anti-doping purposes, or
individuals who for any reason could be subject to doping control testing

- Individuals who are unwilling or unable to provide blood or urine samples

- Individuals who do not actively exercise

- Individuals with any history of cancer, cardiovascular disease, endocrine
abnormalities, infertility, hypoandrogenism, renal disease, hepatic disease,
neurologic disease, or any psychiatric history

- Individuals who have previously used anabolic steroids, selective estrogen receptor
modulators (SERMs), selective androgen receptor modulators (SARMs), or who are
currently using any substances included on the WADA Prohibited List

- History of venous thromboembolic disease (i.e. deep vein thrombosis or pulmonary
embolism)

- History of untreated cataracts

- History of intracranial lesions such as pituitary tumors

- Transaminase elevation greater than 3 times the upper limit of normal (ULN)

- Moderate or heavy alcohol intake
We found this trial at
1
site
Salt Lake City, Utah 84108
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials